TNF and COVID-19: Regarding treatment, rituximab was associated with worse outcome of COVID-19 and most importantly, our data show that treatment with TNF-I was associated with better outcome of COVID-19 compared to the herewith untreated control group, indicating a protective effect of TNF-inhibition against severe COVID-19 disease during the first two waves of pandemic.